Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Beulah Ji"'
Autor:
Sang-Cheol Bae, Damon L. Bass, Myron Chu, Paula Curtis, Richard Dimelow, Laurence Harvey, Beulah Ji, Regina Kurrasch, Saima Muzaffar, Raj Punwaney, David A. Roth, Yeong-Wook Song, Wendy Xie, Fengchun Zhang
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-11 (2022)
Abstract Background Treatment goals for patients with systemic lupus erythematosus (SLE) include minimising disease activity and reducing the risk of flares. Although belimumab is effective at reducing disease activity and risk of severe flares, it w
Externí odkaz:
https://doaj.org/article/ff6acac1a96a455ebd7f0d19e3d58275
Autor:
Anne Hammer, Beulah Ji, David A Roth, David D'Cruz, Paige Meizlik, Gina Eriksson, Yulia Green
Publikováno v:
Lupus Science and Medicine, Vol 10, Iss 1 (2023)
Objective Assess the safety and efficacy of belimumab in older adults with SLE.Methods This post hoc integrated analysis (GSK Study 116559) included safety data from six randomised, placebo-controlled belimumab trials (BLISS-76, BLISS-52, BLISS-SC, N
Externí odkaz:
https://doaj.org/article/238a809959434cd0bbf78b08d243c9e0
Autor:
Christel Wilkinson, Robert B. Henderson, Angela R. Jones-Leone, Shaun M. Flint, Mark Lennon, Roger A. Levy, Beulah Ji, Damon L. Bass, David Roth
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020)
Abstract Background Elevated B lymphocyte stimulator (BLyS) levels in patients with systemic lupus erythematosus (SLE) correlate positively with disease activity; BLyS expression is directly linked to interferon (IFN) pathway activation. This post ho
Externí odkaz:
https://doaj.org/article/0924274602404ad3a219d4663a5e0c26
Autor:
Zhenyu Liang, Nanshan Zhong, Rongchang Chen, Qianli Ma, Yongchang Sun, Fuqiang Wen, Ruth Tal-Singer, Bruce E. Miller, Julie Yates, Jie Song, Chris Compton, Beulah Ji, Li Wu, Yang Yang, Paul Jones, Jinping Zheng
Publikováno v:
ERJ Open Research, Vol 7, Iss 3 (2021)
COPD is heterogeneous, and its presentation varies between countries. The major COPD cohort studies have only been performed in Western populations; the disease is not well characterised in other regions. The COMPASS (Investigation of the Clinical, R
Externí odkaz:
https://doaj.org/article/83fe9c18ba8a4c21991c53101e48da88
Autor:
Damon Bass, Regina Kurrasch, Sang-Cheol Bae, Beulah Ji, David A Roth, Jenny Lowe, Myron Chu, Paula Curtis, Kathleen DeRose, Paige Meizlik
Publikováno v:
RMD Open, Vol 7, Iss 2 (2021)
Objectives To evaluate the long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) from Japan and South Korea.Methods In this phase III, open-label continuation study (BEL114333; NCT01597622), eligible completer
Externí odkaz:
https://doaj.org/article/38e1bf50528c441588e79d0ea8c81c17
Autor:
Chun Hang Tang, Beulah Ji, Ana Malvar, Y K Onno Teng, Brad H. Rovin, Jennifer A Gilbride, Gabriel Contreras, Richard Furie, David M. Roth, Xueqing Yu, Damon Bass, Yulia Green, Tania Gonzalez-Rivera
Publikováno v:
Kidney International, 101(2), 403-413. ELSEVIER SCIENCE INC
We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis (BLISS-LN), a Phase 3, multinational, double-blind, 104-week trial, in which 448 patients with lupus nephritis were randomized to receive intravenous belimumab 1
Autor:
David M. Roth, Susan W Burriss, Michelle Miller, J. Groark, Kathleen Maksimowicz-McKinnon, Luiz Sergio Guedes Barbosa, Amy Pierce, Ellen M. Ginzler, Mittermayer Barreto Santiago, Beulah Ji, Jennifer A Gilbride, Saira Z Sheikh, Richard Furie, Amit Saxena, Jim C. Oates, Damon Bass, David D'Cruz
Publikováno v:
Arthritis & Rheumatology. 74:112-123
Objective Enrollment of patients of Black African ancestry with systemic lupus erythematosus (SLE) in Phase 2 and 3 belimumab trials was not reflective of the racial distribution observed in the lupus population. This study assessed efficacy and safe
Autor:
Raj Punwaney, Sandra V. Navarra, Amy Pierce, Saira Z Sheikh, Ricardo Acayaba de Toledo, Josep Ordi Ros, Roger A. Levy, Ignacio García-De La Torre, Jorge Alfonso Ross Terres, James Cheng-Chung Wei, David M. Roth, Morton Scheinberg, Beulah Ji, Mercedes A. García, Julia Harris, Damon Bass, Alireza Nami, Tamara Mucenic, D. Tegzova, Kevin S. Thorneloe, Kathleen Maksimowicz-McKinnon, Mauricio R Abello Banfi, William Stohl, Carlos Abud-Mendoza
Publikováno v:
The Lancet Rheumatology. 3:e122-e130
Summary Background Belimumab is approved for the treatment of active systemic lupus erythematosus (SLE). Although clinical trials showed a favourable benefit–risk profile, numerical differences in the incidence of mortality and adverse events of sp
Autor:
Xueqing Yu, Nan Chen, Jun Xue, Chi Chiu Mok, Sang-Cheol Bae, Xiaomei Peng, Wei Chen, Hong Ren, Xiao Li, Kajohnsak Noppakun, Jennifer A. Gilbride, Yulia Green, Beulah Ji, Chang Liu, Anuradha Madan, Mohamed Okily, Chun-Hang Tang, David A. Roth
Publikováno v:
American Journal of Kidney Diseases. 81:294-306.e1
Belimumab improved renal outcomes in patients with active lupus nephritis (LN) in BLISS-LN, leading to its approval in the USA and EU. As data on treatment of East Asian patients with LN are limited, we evaluated the efficacy and safety of belimumab
Autor:
David D'Cruz, Gina Eriksson, Yulia Green, Anne Hammer, Beulah Ji, Paige Meizlik, David A Roth
Publikováno v:
Lupus Science & Medicine. 10:e000830
ObjectiveAssess the safety and efficacy of belimumab in older adults with SLE.MethodsThis post hoc integrated analysis (GSK Study 116559) included safety data from six randomised, placebo-controlled belimumab trials (BLISS-76, BLISS-52, BLISS-SC, Nor